论文部分内容阅读
目的:研究培美曲塞在复发性晚期非小细胞肺癌中的应用价值。方法:抽取2011年9月至2013年9月入我院治疗的复发性晚期非小细胞肺癌患者38例作为研究对象,将患者随机分为两组,其中观察组取培美曲塞联合顺铂治疗,对照组取吉西他滨联合顺铂治疗,观察两组患者的临床疗效以及不良用药反应发生率。结果:观察组患者的疾病缓解率为68.42%,对照组患者的疾病缓解率为63.16%,差异无显著差异,不具统计学意义(P>0.05)。观察组患者的恶心、脱发、血红蛋白降低、血小板降低的发生率均较对照组低,差异均具有统计学意义(P<0.05)。结论:两种化疗方案均能够控制疾病的发展,但培美曲塞联合顺铂的用药安全性相对较高,值得推广应用。
Objective: To study the value of pemetrexed in recurrent advanced non-small cell lung cancer. Methods: Thirty-eight patients with recurrent advanced non-small cell lung cancer who were admitted to our hospital from September 2011 to September 2013 were selected as the research object. The patients were randomly divided into two groups. The observation group received pemetrexed combined with cisplatin The control group received gemcitabine plus cisplatin, and the clinical efficacy and the incidence of adverse drug reactions in the two groups were observed. Results: The remission rate was 68.42% in the observation group and 63.16% in the control group, with no significant difference (P> 0.05). Nausea, hair loss, hemoglobin and thrombocytopenia in the observation group were lower than those in the control group, with statistical significance (P <0.05). Conclusion: Both chemotherapy regimens can control the development of the disease. However, the safety of pemetrexed combined with cisplatin is relatively high, which is worthy of promotion and application.